S'abonner

Viraemia and Ebola virus secretion in survivors of Ebola virus disease in Sierra Leone: a cross-sectional cohort study - 17/08/16

Doi : 10.1016/S1473-3099(16)30060-3 
Edward Green, DrMRCP a, , Luke Hunt, MBChB b, J C Gareth Ross, BSc c, Nina Marie Nissen, BSc c, Tanya Curran, PhD d, Anjna Badhan, PhD e, Katherine A Sutherland, PhD f, Jade Richards g, James S Lee, MD h, Samuel H Allen, FRCP i, Steven Laird, MRCP j, Mandy Blackman k, Ian Collacott, BSc l, Paul A Parker, BSc m, Andrew Walbridge, MSc n, Rebecca Phillips, BSc c, Sia Jammie Sellu c, Agnes Dama c, Alpha Karim Sheriff, MBChB c, Joseph Zombo c, Doris Ngegba c, Alieh H Wurie, MD o, Francesco Checchi, PhD c, Timothy J Brooks, FRCPath p
a Tropical and Infectious Diseases Unit, Royal Liverpool University Hospital, Liverpool, UK 
b Liverpool School of Tropical Medicine, Liverpool, UK 
c Save the Children, London, UK 
d Regional Virus Laboratory, Royal Victoria Hospital, Belfast, UK 
e Antiviral Unit, Public Health England, London, UK 
f University College London, London, UK 
g Public Health England Laboratories, Freetown, Sierra Leone 
h University of Alberta, Edmonton, AB, Canada 
i University Hospital Crosshouse, Kilmarnock, UK 
j Worcestershire Royal Hospital, Worcester, UK 
k Kettering General Hospital, Kettering, UK 
l Virology Laboratory, Aberdeen Royal Infirmary, Aberdeen, UK 
m Portsmouth Hospitals NHS Trust, Portsmouth, UK 
n Dorset County Hospital, Dorchester, UK 
o Sierra Leone Ministry of Health, Freetown, Sierra Leone 
p Rare and Imported Pathogens, Public Health England, Porton Down, UK 

* Correspondence to: Dr Edward Green, Tropical and Infectious Diseases Unit, Royal Liverpool University Hospital, Liverpool, L7 8XP, UK Correspondence to: Dr Edward Green Tropical and Infectious Diseases Unit Royal Liverpool University Hospital Liverpool L7 8XP UK

Summary

Background

In survivors of Ebola virus disease, clinical sequelae including uveitis, arthralgia, and fatigue are common and necessitate systematic follow-up. However, the infection risk to health-care providers is poorly defined. Here we report Ebola virus RT-PCR data for body site and fluid samples from a large cohort of Ebola virus survivors at clinic follow-up.

Methods

In this cross-sectional cohort study, consecutive survivors of Ebola virus disease attending Kerry Town survivor clinic (Freetown, Sierra Leone), who had been discharged from the Kerry Town Ebola treatment unit, were invited to participate. We collected and tested axillary, blood, conjunctival, forehead, mouth, rectal, semen, urine, and vaginal specimens for presence of Ebola virus using RT-PCR. We regarded samples to be positive for Ebola virus disease if the cycle threshold was 40 or lower. We collected demographic data from survivors of their age, sex, time since discharge from the treatment unit, and length of acute admission in the Ebola treatment unit using anonymised standard forms.

Findings

Between April 2, and June 16, 2015, of 151 survivors of Ebola virus disease invited to participate, 112 (74%) provided consent. The median age of participants was 21·5 years (IQR 14–31·5) with 34 (30%) participants younger than 16 years. 50 (45%) of 112 participants were male. We tested a total of 555 specimens: 103 from the axilla, 93 from blood, 92 from conjunctiva, 54 from forehead, 105 from mouth, 17 from the rectum, one from semen, 69 from urine, and 21 from the vagina. The median time from Ebola treatment unit discharge to specimen collection was 142 days (IQR 127–159). 15 participants had a total of 74 swabs taken less than 100 days from discharge. The semen sample from one participant tested positive for Ebola virus at 114 days after discharge from the treatment unit; specimens taken from the axilla, blood, conjunctiva, forehead, mouth, rectum, and urine of the same participant tested negative. All specimens from the other 111 participants tested negative.

Interpretation

Patients recovering from Ebola virus disease who do not meet the case definition for acute disease pose a low infection risk to health-care providers 6 weeks after clearance of viraemia. Personal protective equipment after this time might be limited to standard barrier precautions, unless contact with fluids from sanctuary sites is envisaged.

Funding

Save the Children International, Public Health England.

Le texte complet de cet article est disponible en PDF.

Plan


© 2016  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 16 - N° 9

P. 1052-1056 - septembre 2016 Retour au numéro
Article précédent Article précédent
  • Reassessment of the positive predictive value and specificity of Xpert MTB/RIF: a diagnostic accuracy study in the context of community-wide screening for tuberculosis
  • Jennifer Ho, Phuong Thi Bich Nguyen, Thu Anh Nguyen, Khoa Hien Tran, Son Van Nguyen, Nhung Viet Nguyen, Hoa Binh Nguyen, Khanh Boi Luu, Greg J Fox, Guy B Marks
| Article suivant Article suivant
  • Risk of reproductive complications following chlamydia testing: a population-based retrospective cohort study in Denmark
  • Bethan Davies, Katy M E Turner, Maria Frølund, Helen Ward, Margaret T May, Steen Rasmussen, Thomas Benfield, Henrik Westh, Danish Chlamydia Study Group †

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.